Abstract：OBJECTIVE To investigate the biomolecular anti-diabetes mechanism and its complications of celastrol based on bioinformatics database. METHODS The related genes of celastrol were obtained from the bioinformatics database, the cross-related genes of celastrol and diabetes mellitus were searched by Veen diagram software, the protein-protein interaction network was constructed by STRING software, the related KEGG pathway was identified by the DAVID software and KOBAS software, and the molecular network of anti-diabetes "compound-target gene-pathway-disease" was further constructed by R program software. RESULTS There were 50 genes related to diabetes in celastrol, and 11 related pathways (P<0.001), which mainly affected the AGE-RAGE signaling pathway in diabetic complications. The mechanism was to regulate AGE-RAGE-NF-κB axis by inhibiting NF-κB, which reduced the production of downstream inflammatory effectors, insulin resistance and fibrotic damage. CONCLUSION Celastrol can improve the symptoms of diabetes and its complications by regulating the AGE-RAGE-NF-κB axis-related signaling pathway, which is expected to be a potential drug for the treatment of diabetes and its complications.
袁永亮, 李泽运, 杜玥, 张基, 杨志衡, 田鑫. 基于生物信息数据库探讨雷公藤红素抗糖尿病及其并发症的生物分子机制研究[J]. 中国药学杂志, 2020, 55(4): 305-311.
YUAN Yong-liang, LI Ze-yun, DU Yue, ZHANG Ji, YANG Zhi-heng, TIAN Xin. Bio-molecular Mechanism of Celastrol Anti-diabetes and Its Complications Based on Biological Information Database. Chinese Pharmaceutical Journal, 2020, 55(4): 305-311.
COOPER T A, WAN L, DREYFUSS G. RNA and disease[J]. Cell, 2009, 136(4):777-793.
CONSULTATION W. Definition, diagnosis and classifications of diabetes mellitus and its complications[J]. Diabetic Med, 1999, 15(7):539-553.
TING G, JUAN T, HUI-JIE B, et al. Cross and integration of systems medical biology in biomedicine[J]. Chin Pharm J (中国药学杂志), 2013, 48(23):1977-1979.
LI Q Y, SHI-BING S U. Application of systems biology in traditional chinese medicine research[J]. World Sci Technol, 2008, 10(4):1-6.
CORSON T W, CREWS C M. Molecular understanding and modern application of traditional medicines: triumphs and trials[J]. Cell, 2007, 130(5):769-774.
KANNAIYAN R, SHANMUGAM M K, SETHI G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer[J]. Cancer Lett, 2011, 303(1):9-20.
ALLISON A C, CACABELOS R, LOMBARDI V R, et al. Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease[J]. Prog Neuropsychopharmacol Biol Psych, 2001, 25(7):1341-1357.
PANG X F, YI Z F, JING Z, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway[J]. Cancer Res, 2010, 70(5):1951-1959.
NA L, TIAN-DONG Z, YUE-FENG W, et al. Celastrol triggers autophagy in human cervical cancer hela cells in vitro and in vivo[J]. Chin Pharm J (中国药学杂志), 2018, 53(7):513-517.
LIU J, LEE J, SALAZARHERNANDEZ M A, et al. Treatment of obesity with celastrol[J]. Cell, 2015, 161(5):999-1011.
HUANG M. The mechanism research of Celastrol lowers blood glucose in diabetic mice[D]. Wuhan:Hubei University of Technology, 2013.
KIM J E, MI H L, NAM D H, et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice[J]. PLoS One, 2013, 8(4):e62068.
LIAO W T, XIAO X Y, ZHU Y, et al. The effect of celastrol on learning and memory in diabetic rats after sevoflurane inhalation[J]. Arch Med Sci Am, 2018, 14(2):370-380.
HAN L P, LI C J, BEI S, et al. Protective effects of celastrol on diabetic liver injury via TLR4/MyD88/NF-κB signaling pathway in type 2 diabetic rats[J]. J Diabetes Res, 2016, 2016: 1-10.
MIN Z. Celastrol attenuates renal injury in diabetic rats by inhibiting the MAPK/NF-κB signaling pathway[D]. Xianyang:Shaanxi University of Chinese Medicine, 2018.
RU J, LI P, WANG J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6(1):13-19.
SAFRAN M, DALAH I, ALEXANDER J, et al. GeneCards Version 3: the human gene integrator[J]. Database, 2010, 2010:baq020.
KUHN M, SZKLARCZYK D, FRANCESCHINI A, et al. STITCH 3: zooming in on protein-chemical interactions [J]. Nucleic Acids Res, 2012, 40(database issue):876-880.
PIERO J, QUERALTROSINACH N, BRAVO , et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes[J]. Database, 2015, 2015(3):v28.
FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration[J]. Nucleic Acids Res, 2013, 41(Database issue):D808-D815.
HUANG D W, SHERMAN B T, STEPHENS R, et al. DAVID gene ID conversion tool[J]. Bioinformation, 2008, 2(10):428-430.
XIE C, MAO X, HUANG J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases[J]. Nucleic Acids Res, 2011, 39(web server issue):316-322.
QING-YUAN M, WEI-DON L, XIANG-FAN H. The relationship between AGE-RAGE system and pathogenesis of diabetic foot syndrome,and advance on treatment[J]. Pharm Care Res(药学服务与研究), 2009, 9(2):118-121.
KIM J E, LEE M H, NAM D H, et al. Celastrol, an NF-kB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice[J]. PLoS One, 2013, 8(4):e62068.
YAMAMOTO Y, YAMAGISHI S I, YONEKURA H, et al. Roles of the AGE-RAGE system in vascular injury in diabetes[J]. Ann Ny Acad Sci, 2010, 902(1):163-172.
SHO-ICHI Y, KAZUO N, TAKANORI M. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy[J]. Curr Drug Discov Technol, 2006, 3(1):83-88.
HUIJBERTS M S, SCHAPER N C, SCHALKWIJK C G. Advanced glycation end products and diabetic foot disease [J]. Diabete Metab Res Rev, 2010, 24(S1):19-24.
WADA R, YAGIHASHI S, BAYNES J W, et al. Role of advanced glycation end products and their receptors in development of diabetic neuropathy [J]. Ann Ny Acad Sci, 2010, 1043(1):598-604.
TANG M, CAO X, ZHANG K, et al. Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression[J]. Cell Death Dis, 2018, 9(6):601.
BAKAR M H, SARMIDI M R, TAN J S, et al. Celastrol attenuates mitochondrial dysfunction and inflammation in palmitate-mediated insulin resistance in C3A hepatocytes[J]. Eur J Pharmacol, 2017, 799: 73-83.
ABU BAKAR M H, CHENG K K, SARMIDI M R, et al. Celastrol protects against antimycin a-induced insulin resistance in human skeletal muscle cells[J]. Molecules, 2015, 20(5):8242-8269.
HAN L P, SUN B, LI C J, et al. Effect of celastrol on toll-like receptor 4-mediated inflammatory response in free fatty acid-induced HepG2 cells[J]. Int J Mol Med, 2018, 42(4):2053-2061.
YU X, WANG Q, ZHOU X, et al. Celastrol negatively regulates cell invasion and migration ability of human osteosarcoma via downregulation of the PI3K/Akt/NF-κB signaling pathway in vitro[J]. Oncol Lett, 2016, 12(5):3423-3428.